Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation.
Nie W, Gan L, Wang X, Gu K, Qian FF, Hu MJ, Zhang D, Chen SQ, Lu J, Cao SH, Li JW, Wang Y, Zhang B, Wang SY, Li CH, Yang P, Xu MD, Zhang XY, Zhong H, Han BH.
Nie W, et al. Among authors: zhang b, zhang d, zhang xy.
Oncoimmunology. 2021 Jan 15;10(1):1865670. doi: 10.1080/2162402X.2020.1865670.
Oncoimmunology. 2021.
PMID: 33537171
Free PMC article.